{"filing":{"accession_number":"0001193125-26-289409","cik":"0001623526","ticker":"STOK","company_name":"Stoke Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"d924679d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526289409/d924679d8k.htm"},"events":[{"id":14843,"run_id":13234,"accession_number":"0001193125-26-289409","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Stoke Therapeutics announced completion of enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with anticipated Phase 3 data readout in Q3 2027 and planned rolling NDA submission to the FDA beginning Q1 2027. This represents a material clinical development milestone for the company's lead investigational medicine.","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12403,"accession_number":"0001193125-26-289409","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of enrollment in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with plans for NDA submission in Q1 2027 and Phase 3 data readout in Q3 2027. This is a material clinical development milestone for a lead investigational medicine, but does not fit the specific event types (earnings, M\u0026A, impairment, etc.). As a significant operational/clinical milestone affecting the company's development timeline and regulatory pathway, it is best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:03:42.555582+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12404,"accession_number":"0001193125-26-289409","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with anticipated Phase 3 data readout in Q3 2027 and planned rolling NDA submission to the FDA beginning Q1 2027. This is a material clinical development milestone for a lead investigational medicine, but does not fit the specific event types of earnings release, M\u0026A activity, material impairment, or other defined categories. It is clearly an operational/strategic milestone in the drug development process that would affect a reasonable investor's assessment of the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:03:42.555582+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12403,"accession_number":"0001193125-26-289409","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of enrollment in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with plans for NDA submission in Q1 2027 and Phase 3 data readout in Q3 2027. This is a material clinical development milestone for a lead investigational medicine, but does not fit the specific event types (earnings, M\u0026A, impairment, etc.). As a significant operational/clinical milestone affecting the company's development timeline and regulatory pathway, it is best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:03:42.555582+00:00","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-06-30"},{"id":12404,"accession_number":"0001193125-26-289409","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with anticipated Phase 3 data readout in Q3 2027 and planned rolling NDA submission to the FDA beginning Q1 2027. This is a material clinical development milestone for a lead investigational medicine, but does not fit the specific event types of earnings release, M\u0026A activity, material impairment, or other defined categories. It is clearly an operational/strategic milestone in the drug development process that would affect a reasonable investor's assessment of the company's progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:03:42.555582+00:00","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-06-30"}]}